---
title: "Akeso's ivonescimab receives fifth Breakthrough Therapy Designation for treating advanced biliary tract cancer. #innovation #healthcare"
description: "In Hong Kong on February 5, 2026, Akeso, Inc.announced that ivonescimab, a groundbreaking bispecific antibody targeting PD-1 and VEGF, has received its fifth Breakthrough Therapy Designation from the "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275063535.md"
published_at: "2026-02-06T02:28:40.000Z"
---

# Akeso's ivonescimab receives fifth Breakthrough Therapy Designation for treating advanced biliary tract cancer. #innovation #healthcare

> In Hong Kong on February 5, 2026, Akeso, Inc.announced that ivonescimab, a groundbreaking bispecific antibody targeting PD-1 and VEGF, has received its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE).

In Hong Kong on February 5, 2026, Akeso, Inc. (9926.HK) announced that ivonescimab, a groundbreaking bispecific antibody targeting PD-1 and VEGF, has received its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE).

### Related Stocks

- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [513700.CN - Penghua CSI HK Connect Health Care Composite ETF](https://longbridge.com/en/quote/513700.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BeOne Medicines posts 2025 results and issues cautious 2026 outlook | BeOne Medicines Ltd, a biopharmaceutical company based in Switzerland and listed in Hong Kong, has released its unaudite | [Link](https://longbridge.com/en/news/277035413.md) |
| Top Eminent Healthcare to Acquire Online Healthcare Platform in HK$100.3 Million Connected Deal | Top Eminent Healthcare Group Limited will acquire 100% of Top Eminent II Limited for HK$100.3 million, a connected trans | [Link](https://longbridge.com/en/news/277135842.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/en/news/276718382.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.